OBJECTIVE: The aim of the study was the assessment of adherence to antiretroviral (ARV) treatment in a population of people living with HIV (PWH), improving the awareness of PWH, drawing attention to the risk of developing HIV drug resistance and subsequent treatment failure. METHODS: The basic cohort consisted of PWH followed up long-term at the HIV centre of the University Hospital Pilsen. Adherence to treatment was assessed by ARV levels. Nucleoside analogs were determined in urine by high pressure liquid chromatography (HPLC), in relation to clinical data, viral load (HIV RNA), and absolute CD4 and CD8 T cell counts. To assess mental and physical state of the patients, a modified SF-36 questionnaire was used to measure social relationships, education and ability to relax. RESULTS: From a group of 131 PWH, 18 (13.7%) with zero levels and 113 (86.3%) with any detectable ARV levels were followed for 6-12 months. A statistically significant lower viral load was demonstrated in patients who adhered to the treatment at the time of the test as indicated by ARV levels in the urine. CD4 T lymphocyte values in adherent patients were, as expected, statistically significantly higher. A significant difference for CD8 T lymphocyte was not demonstrated. A survey assessed subjective factors influencing the degree of adherence. PWH consider important: quality care enabling trust, low risk of developing opportunistic infections, self-sufficiency, quality of sleep, managing leisure activities, and good family relationships. Quality of life evaluation and satisfaction in the monitored areas were similar in both groups of PWH. CONCLUSIONS: Non-adherence leads to deterioration of CD4 and viral load levels and may be the cause of the development of HIV drug resistance and treatment failure on the part of the patient. PWH with zero or low urinary nucleoside levels were repeatedly instructed about the need for regular and sustained medication use. Regular checks with a laboratory examination service are needed to detect early emergence of resistance and side effects of the treatment, which are initially only detectable in the laboratory.

Department of Infectious Diseases and Travel Medicine Faculty of Medicine in Pilsen Charles University and University Hospital Pilsen Pilsen Czech Republic

Faculty of Health Studies University of Western Bohemia Pilsen Czech Republic

National Institute of Public Health Prague Czech Republic

Zobrazit více v PubMed

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.

Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.

Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults 2016: recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316(2):191-210.

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830-9.

Sedláček D, Stehlík P, Stožický F. [Contribution to the control of antiretroviral adherence treatment]. Klin Mikrobiol Inf Lék. 2001;7(3):80-2. Czech.

[Code list - Quick overview in a wide range of industries] [Internet]. Artega o. s. [cited 2017 Aug 27]. Available from: http://ciselnik.artega.cz/vzdelani_obyvatel_cr.php. Czech.

Waitt C, Diliiy Penchala S, Olagunju A, Amara A, Else L, Lamorde M, et al. Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1060:300-7.

Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011;52(10):1267-75.

Koal T, Burhenne H, Römling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(21):2995-3001.

Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng JH, et al. Emtricitabine-triphosphate in dried blood spots as a marker of recent dosing. Antimicrob Agents Chemother. 2016;60(11):6692-7.

D'Avolio A, Simiele M, Siccardi M, Baietto L, Sciandra M, Oddone V, et al. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. J Pharm Biomed Anal. 2011;54(4):779-88.

Koenig HC, Mounzer K, Daughtridge GW, Sloan CE, Lalley-Chareczko L, Moorthy GS, et al. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. HIV Med. 2017;18(6):412-8.

Cressey TR, Siriprakaisil O, Klinbuayaem V, Quame-Amaglo J, Kubiak RW, Sukrakanchana PO, et al. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study. BMC Infect Dis 2017;17(1):496. doi: 10.1186/s12879-017-2593-4. DOI

Patel K, Nagel M, Wesolowski M, Dees S, Rivera-Milla E, Geldmacher Ch, et al. Evaluation of a urine-based rapid molecular diagnostic test with potential to be used at point-of-care for pulmonary tuberculosis: Cape Town cohort. J Mol Diagn. 2018;20(2):215-24.

Gandhi M, Bacchetti P, Rodrigues WC, Spinelli M, Koss CA, Drain P K, et al. Development and validation of an immunoassay for tenofovir in urine as a real-time metric of antiretroviral adherence. EClinicalMedicine. 2018;2-3:22-8.

Gurková E. [Quality of life assessment: for clinical practice and nursing research]. 1st ed. Prague: Grada; 2011. Czech.

Frei J. [The importance of treatment adherence in relation to the quality of life of HIV patients]. Florence. 2013;9(10):26-30. Czech.

Nelsen A, Gupta S, Trautner BW, Petersen NJ, Garza A, Giordano TP, et al. Intention to adhere to HIV treatment: a patient-centred predictor of antiretroviral adherence. HIV Med. 2013;14(8):472-80.

Frei J, Sedláček D. [The impact of treatment adherence on the quality of life of HIV positive patients]. In: Proceedings of the International Symposium Research in Nursing; 2014 Sep 26; Brno, Czech Republic. Brno: Masaryk University; 2024. p. 22-4. Czech.